Global Patterns, Temporal Trends, and Potential Non-Infectious Risk Factors for Burkitt Lymphoma from 1990 to 2021 [0.03%]
1990至2021年Burkitt淋巴瘤的全球模式、时间趋势及其潜在非传染性危险因素
Shi-Kai Jin,Jun-Ting Lyu,Zi-Yu Feng et al.
Shi-Kai Jin et al.
Background: The heterogeneity in the health burden and non-infectious risk factors of Burkitt lymphoma (BL) across sex, age, and geographic distribution remain inadequately understood. ...
Expression and Clinical Significance of BCL2 Interacting Protein 3 Like (BNIP3L) in Serum of Patients with MM [0.03%]
MM患者血清BNIP3L表达及其临床意义
Yanyu Nong,Zengyi Xiong,Qicai Wang et al.
Yanyu Nong et al.
Background: BNIP3L regulates mitophagy and apoptosis, and its dysregulation is closely linked to the development and progression of cancers. Studies have shown that BNIP3L is valuable for assessing tumor progression and p...
LRG1 Drives AML Progression by Disrupting Myeloid Progenitor Regulation [0.03%]
LRG1通过干扰粒系祖细胞调控促进急性髓系白血病进展
Rongxia Guo,Peng Wu,Shuxin Yao et al.
Rongxia Guo et al.
Background: Acute myeloid leukemia (AML) remains clinically challenging due to its molecular heterogeneity and poor outcomes, highlighting the urgent need for novel biomarkers and therapeutic targets. ...
Alantolactone Inhibits Double Expression Lymphoma via Dual-Targeted Glycogen Synthase Kinase 3 Beta and B-Cell Lymphoma2 [0.03%]
阿尔托龙通过双重靶向糖原合酶激酶3β和B细胞淋巴瘤2抑制双表达淋巴瘤
Jianhua Chen,Qing Liao,Sha Yang et al.
Jianhua Chen et al.
Background: Dual-expression lymphoma (DEL) is an aggressive subtype with concurrent MYC and BCL2 overexpression. This disease exhibits a poor prognosis and responds poorly to standard R-CHOP therapy,highlighting the urgen...
Phase II Trial of an Orelabrutinib-Based Combination Therapy in Newly Diagnosed Primary Central Nervous System Lymphoma [0.03%]
奥雷布替尼联合方案治疗新诊断原发中枢神经系统淋巴瘤II期临床研究
Yajing Zhao,Xinguang Liu,Qiang He et al.
Yajing Zhao et al.
Purpose: Primary central nervous system lymphoma (PCNSL) is a rare, yet highly aggressive non-Hodgkin lymphoma confined to the central nervous system (CNS). High-dose methotrexate (HD-MTX) remains the baseline chemotherap...
Venetoclax Plus Blinatumoma as First Line Therapy for Newly Diagnosed Ph-Negative B-Cell Acute Lymphoblastic Leukemia [0.03%]
维奈克拉联合博纳吐单抗作为新诊断Ph阴性B细胞急性淋巴细胞白血病初治方案
Yutian Lei,Xiaoli Zhao,Huijun Huang et al.
Yutian Lei et al.
Purpose: This study evaluated the efficacy and safety of a 14-day blinatumomab-venetoclax (BV) regimen as induction therapy for newly diagnosed Ph-negative B-cell acute lymphoblastic leukemia (B-ALL), focusing on rapid re...
The Ongoing Challenges of Managing Cytopenic Myelofibrosis in 2025: The Emergence of Non-JAK Inhibitor Therapies [0.03%]
2025年环孢素样贫血性骨髓纤维化的管理面临的挑战：非JAK抑制剂治疗的出现
Samuel B Reynolds,Rami Komrokji,Andrew T Kuykendall
Samuel B Reynolds
Primary myelofibrosis (PMF) is a myeloproliferative neoplasm that is felt to arise from somatic mutations with hematopoietic stem and progenitor cells (HSPC's), leading to the development of atypical megakaryocytic hyperplasia. Associated d...
Comprehensive Analysis of Tumor Microenvironment and PD-L1 Expression Associations with Clinicopathological Features and Prognosis in Diffuse Large B-Cell Lymphoma [0.03%]
弥漫性大B细胞淋巴瘤中肿瘤微环境及PD-L1表达与临床病理特征和预后的综合分析
Yun-Li Xie,Long-Feng Ke,Wen-Wen Zhang et al.
Yun-Li Xie et al.
Introduction: The tumor microenvironment (TME) influences diffuse large B-cell lymphoma (DLBCL) progression, but the prognostic roles of tumor-infiltrating T-lymphocytes (TIL-T), tumor-associated macrophages (TAMs), and P...
Comprehensive Evaluation of Drug-Related Problems and Pharmacotherapy Patterns in Non-Hodgkin's Lymphoma Patients in Yemen [0.03%]
也门非霍奇金淋巴瘤患者药物相关问题及用药模式的全面评估
Mohammed Mohammed Battah,Hadzliana Zainal,Doa&#x;a Anwar Ibrahim et al.
Mohammed Mohammed Battah et al.
Background: Drug-related problems (DRPs) are critical challenges in oncology practice, particularly among patients with non-Hodgkin lymphoma (NHL), due to complex regimens and high toxicity potential. ...
Serum ATIC Expression as a Novel Diagnostic and Prognostic Biomarker in Multiple Myeloma Patients [0.03%]
血清ATIC表达作为多发性骨髓瘤患者新型诊断和预后生物标志物的研究
Mengyuan Gu,Yanting Zheng,Yifan Wang et al.
Mengyuan Gu et al.
Purpose: The study was constructed for investigating the serum expression levels of ATIC with multiple myeloma (MM) patients and its potential clinical value as a biomarker, and analyzing its association with disease stag...